About Marizyme
Bridging the Gap Between Advanced Medical Technology and Clinical Practice.
Marizyme is dedicated to transforming the landscape of cardiac care. Our core mission is to safeguard patient outcomes by neutralizing oxidative damage—the primary mediator of surgical ischemic injury. We develop first-in-class vascular conduit solutions that address the most critical challenges in Coronary Artery Bypass Grafting (CABG).
Our core mission is to safeguard patient outcomes through the maintenance of vascular integrity, utilizing a proprietary platform designed to neutralize oxidative damage—the primary mediator of surgical ischemic injury.
Clinical Innovation: Developer of DuraGraft - the first and only FDA-cleared vascular conduit solution to maintain the structural and functional integrity of saphenous vein grafts.
Clinical Evidence: Our technology addresses the root cause of graft failure. Clinical data demonstrates significantly less wall thickening at 12 months post-CABG compared to saline.
Fiscal Resilience: We strive to provide hospital systems with a strategic tool to reduce the financial burden of repeat procedures and extended hospital stays.
Built for Leadership: With a patent portfolio spanning 30+ countries and national agreements with networks, we are built for long-term market leadership.